BRAF V600E mutation was present in 17 patients overall (0.3%), including 11 patients in the STS cohort (0.3%), five patients in the GIST cohort (0.5%), and one in the uterine sarcoma cohort (0.2%). This evidence concerns the gene BRAF and gastrointestinal stromal tumor.